TRV 734

Drug Profile

TRV 734

Alternative Names: TRV734

Latest Information Update: 02 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trevena
  • Class Analgesics; Small molecules
  • Mechanism of Action Beta arrestin inhibitors; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 02 Jun 2015 Trevena has patent protection for compositions and methods of use of TRV 734 in USA
  • 30 Mar 2015 Trevena completes a phase I trial in Healthy volunteers in USA (NCT02411500)
  • 09 Feb 2015 Pharmacokinetics and adverse events data from a phase I trial in healthy volunteers released by Trevena
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top